Evidence map›Paper›PMID 18686739›Full record

Trial reportInternational journal of chronic obstructive pulmonary disease2008

Effect of tiotropium on health-related quality of life as a primary efficacy endpoint in COPD.

A-B Tonnel, T Perez, J-M Grosbois, C Verkindre, M-L Bravo, M Brun, TIPHON study group

Open access · goldAbstract readComparative StudyMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in International journal of chronic obstructive pulmonary disease, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers, 18 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
44citing papers in PubMed, 18 pooled it
6.3field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

44 citing papers in PubMed, 18 syntheses or guidelines pooled it, 81 citations in OpenAlex.

  1. What conservative interventions can improve the long-term quality of life, depression, and anxiety of individuals with stable COPD? A systematic review and meta-analysis.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2022
    Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Comparative efficacy of combination bronchodilator therapies in COPD: a network meta-analysis.International journal of chronic obstructive pulmonary disease · 2015
    Pooled it
  10. Tiotropium versus placebo for chronic obstructive pulmonary disease.The Cochrane database of systematic reviews · 2014
    Pooled it
  11. Pooled it
  12. Pooled it
  13. Pooled it
  14. Pooled it
  15. Copd.BMJ clinical evidence · 2011
    Pooled it
  16. Pooled it
  17. Pooled it
  18. Pooled it
  19. Trial
  20. Trial
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

A-B TonnelCentre Hospitalier Régional Universitaire (CHRU) de Lille, Service de Pneumologie et Immuno-Allergologie, Lille Cedex, France. ab-tonnel@chru-lille.fr
T Perez
J-M Grosbois
C Verkindre
M-L Bravo
M Brun
TIPHON study group
Centre Hospitalier Universitaire de Lille · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Clinical manifestations of chronic obstructive pulmonary disease (COPD), including airflow limitation, dyspnea, and activity limitation, ultimately lead to impaired health-related quality of life (HRQoL). This 9-month, randomized, double-blind, multicenter study compared the effect of once-daily tiotropium 18 microg and placebo on HRQoL, spirometric parameters, and exacerbations in 554 patients with moderate-to-severe COPD. HRQoL was assessed using the St. George's Respiratory Questionnaire (SGRQ) and the new 8-item Visual Simplified Respiratory Questionnaire (VSRQ), which is currently being validated. The primary efficacy endpoint was the proportion of patients achieving a reduction of at least 4 units in the SGRQ total score at study end (Month 9). Mean +/- SD baseline SGRQ total score was 47.4 +/- 18.1. Significantly more tiotropium-treated patients achieved a reduction of at least 4 units in the SGRQ score vs placebo at study end (59.1% vs 48.2%, respectively; p = 0.029). Tiotropium significantly improved spirometric parameters (forced expiratory volume in 1 second [FEV1]: 0.11 +/- 0.02 L vs 0.01 +/- 0.02 L; between-group difference: 0.10 +/- 0.03 L, p = 0.0001) and reduced exacerbations vs placebo. Maintenance treatment with tiotropium provided significant and clinically relevant improvements in HRQoL, as measured by the SGRQ.

Indexed as

Quality of LifeCholinergic AntagonistsDelayed-Action PreparationsDose-Response Relationship, DrugDouble-Blind MethodFemaleFollow-Up StudiesForced Expiratory Flow RatesHumansMaleMiddle AgedPulmonary Disease, Chronic ObstructiveRetrospective StudiesScopolamine DerivativesSurveys and QuestionnairesTime FactorsCholinergic AntagonistsDelayed-Action PreparationsScopolamine DerivativesTiotropium Bromide

Identifiers

PMID18686739
PMCPMC2629970
OpenAlexW1954671479

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.